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Options for the Development 
of a PET/CT Program in NL
Positron emission tomography (PET) is a 
type of Nuclear Medicine (NM) imaging 
technology that allows true imaging of 
human physiological and biochemical 
processes.  
At present, patients in Newfoundland 
and Labrador who require a PET scan 
must travel out of the 
province to either 
Alberta or Quebec at a 
substantial cost to the 
provincial health system 
as well as to the patient 
and his/her family. 
While the recorded number of NL 
residents who received PET scans in the 
past has been relatively small (fewer than 
35 patients per year since 2004), these 
numbers may not represent the true 
size of the population that might have 
benefited from PET nor provide a reliable 
guide to future demand.
Today, PET scanners are most often 
available only as ‘hybrid’ models that 
combine PET with computed tomography 
(CT). When PET is combined with 
CT, the fused images allow accurate 
simultaneous visualization of function 
or physiology (in the PET element) and 
anatomy or structure (in the CT element). 
A technology closely associated with 
PET scanning is a medical 
cyclotron; Locating a PET 
scanner close to a cyclotron 
is important for its clinical and 
research utility. 
This report was initially 
designed to examine research-
based evidence about whether the 
province of NL should acquire a PET 
scanner. Given that the Government 
of NL has announced its intention to 
purchase a PET scanner and a medical 
cyclotron, and that a further decision 
has been reached to locate both pieces 
of equipment in St. John’s, our focus has 
been on a set of ancillary, but still very 
important, issues that contribute to the 
primary research question, below.
The Newfoundland and Labrador 
Centre for Applied Health 
Research is working with decision 
makers in the provincial health 
system to identify and address 
issues of pressing interest to 
Newfoundland and Labrador 
on which guidance from the 
research evidence is important. 
These issues are being addressed 
through the Contextualized 
Health Research Synthesis 
Program (CHRSP).
CHRSP analyzes the findings of 
high-level research (systematic 
reviews, meta-analyses and health 
technology assessments) that 
has already been done on the 
issue in question. The findings 
of these studies are synthesized 
and are subjected to a systematic 
process of ‘contextualization’: they 
Given the geographic, demographic, fiscal and political 
context of Newfoundland and Labrador, what is the 
most appropriate, effective, and efficient way to 
operate a PET/CT program so that the population 
derives the maximum benefit at the best possible cost? 
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Sources of evidence
The sources of evidence for this research synthesis are limited 
to systematic reviews, health technology assessments, and 
a few very recent original studies for the most commonly 
published indications for FDG PET/CT imaging in adults. Most 
of the literature is 
oncology-related, 
with limited 
discussions of cardiac 
and neurological 
indications. 
A recent 
comprehensive 
systematic review by 
Facey et al. (2007) 
of PET and PET/CT 
for selected cancers 
is, unless otherwise 
specified, the principal 
source of information 
for this report. 
Preliminary findings 
from the synthesis
There is good 
evidence that FDG 
PET/CT is beneficial 
in the management 
of many types of cancer. The strongest evidence relates to 
the characterization of indeterminate pulmonary nodules (to 
assess the risk of cancer), staging of lung cancer,  restaging of 
colorectal cancer, and the staging, assessment of response and 
restaging of lymphoma (cancer of the lymph nodes). There 
is also reasonable and growing evidence on the limited use 
of FDG PET/CT for specific neurological (e.g., epilepsy and 
dementia) and cardiac (e.g., chronic ischemia) indications.
Clinical practice guidelines
On the basis of current best evidence and professional 
consensus, agencies in North America and Britain have 
developed clinical practice guidelines (CPG) for FDG PET and 
PET/CT scanning for select cancer, neurological, and cardiac 
indications (see Table 3 in the full report). Guided by these 
CPGs, NL will have to determine its own list of indications for 
PET scans and modify it as appropriate to include emerging 
indications in the future. 
Benefits
Although PET/CT is largely an adjuvant imaging modality, 
cost savings may be realized in that PET/CT scanning can 
significantly influence patient management by providing an 
opportunity to avoid futile and costly, invasive interventions 
(e.g., surgery or radical radiotherapy) and to provide more 
appropriate palliative therapy, thus increasing the patient’s 
quality of life despite not improving overall survival. 
How PET/CT is used
There are currently three broad categories of accepted clinical 
application for PET/CT technology:
in oncology imaging,  to help determine how extensive a 1. 
cancer is, whether it has responded to therapy, and whether 
it has recurred;
in brain imaging, for select patients with seizure disorders 2. 
and for the early detection of dementia; and
in cardiac imaging,  to assess the viability of heart muscle3. .
Demand for PET/CT
PET/CT imaging is publicly funded throughout Canada, though 
not all provinces have PET/CT scanners. According to CADTH 
(January, 2008), PET/CT scanners are located in all provinces 
and territories of Canada except Saskatchewan, PEI, Yukon, 
NWT, Nunavut, and NL (see the full report for details).  A 
limited number of cyclotrons are located across the country. 
The Canadian regulatory environment for the production of 
FDG (see box, below) and other PERs is complicated, and 
Health Canada (HC) requires new producers to conduct 
clinical trials to prove both the safety and the clinical 
efficacy of their PERs for specific indications. A list of the 
HC-approved indications for the use of FDG in PET and a list 
of the indications that are currently in approved clinical trial 
applications are available in the full CHRSP report. 
PET/CT imaging research is a rapidly growing field and 
there are new emerging indications for this technology. It is, 
therefore, difficult 
to predict the 
future demand for 
FDG PET/CT scans 
in NL accurately. 
Demographically, 
the trend toward an 
aging population in 
this province, and the 
associated increased 
incidences of cancers 
and dementia, will 
likely be a major 
driver of the demand 
for this technology in 
the future. 
The full report on 
this project provides 
a detailed analysis of the estimated demand for PET/CT scans, 
based on the currently approved or accepted indications, 
and suggests that NL ought to plan for sufficient funding and 
services for 600 – 1200 PET scans annually for oncology 
indications and less than 10 scans for seizure disorders. 
However, anticipated increases in demand for brain imaging 
for dementia, the development of new PERs, and an aging 
population, mean that demand for PET scanning for current and 
additional indications can be expected to increase significantly.
Background
About PET/CT What We Looked At
Focus of the Synthesis
  
Secondary research questions for this 
synthesis
where, within the St. John’s area, should the   •
 new equipment be located? 
for what clinical indications is PET currently the   •
 best choice in terms of clinical effectiveness and  
 cost-effectiveness? 
what other indications are emerging for which   •
 it makes sense to plan for PET use? 
what is the optimal method for organizing and   •
 managing access to PET scans?
what are the advantages of early development   •
 of a cyclotron program and  the challenges of  
 operating without one?
what are the requirements of a PET/CT scanning   •
 program in terms of  professional competencies  
 for physicians and technologists, training,   
 financing and space? 
what is the optimal sequencing of the activities   •
 required for effective acquisition,  installation,  
 licensing and start-up of a PET/CT scanning   
 program? 
What is a cyclotron and why is it 
important to PET/CT?
A technology closely associated with PET scanning is 
a medical cyclotron which produces positron-emitting 
radioisotopes which are subsequently processed to 
produce positron emitting radiopharmaceuticals (PERs) 
containing a radioactive isotope. 
The process of PET/CT imaging begins by injecting 
the patient with trace amounts of these PERs 
isotopes that, unlike the majority of commonly used 
radiopharmaceutical isotopes, generally have quite 
short half-lives1. 
Radiolabeled glucose or fluorodeoxyglucose (FDG) is 
the primary PER currently used for oncology imaging 
and it has a half-life of 110 minutes. The other 
common positron isotopes have half-lives ranging 
from 2 to 20 minutes. Locating a PET scanner close to 
a cyclotron is important for its clinical and research 
utility. If NL had a PET/CT but not a cyclotron, the 
province would be dependent on radioactive isotopes 
flown in from elsewhere.
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Impact on research
PET/CT, in combination with a medical cyclotron program, is a 
powerful research tool with the potential to enhance research 
capacity and improve recruitment and retention of Nuclear 
Medicine and other specialist physicians, technologists, and 
academics.  The introduction of PET/CT scanning in NL will also 
enhance the eligibility of patients for certain types of clinical 
trials (e.g., in oncology) that would otherwise not be open to 
them.
Guided by Dr. Demeter’s experience in developing the 
Winnipeg PET/CT program, the synthesized evidence on PET/
CT was applied to the NL context, providing guidance about 
the essential components of both a PET/CT and a cyclotron 
program and about optimal timelines and sequencing. The 
contextualized evidence was further verified by consultations 
with leaders in the development of the Halifax PET/CT program.
Locating the PET/CT program
Based on population demographics, distribution of services, 
availability of medical and support personnel, and research 
potential, St. John’s is the most appropriate location for the PET/
CT scanner and cyclotron. The Winnipeg experience suggests 
that the PET/CT suite should be located in a tertiary acute care 
setting from the outset. 
Local oncologists in NL are eager to provide input into the 
design of the PET/CT suite, particularly as it relates to specific 
considerations for both adult and pediatric patients. Both 
Winnipeg and Halifax use approximately 2000 sq. ft. for their 
PET/CT suite. The suite should be located as close as possible 
to the cyclotron facility to allow for rapid delivery of short-
lived PERs, not only for clinical purposes, but to facilitate basic 
science and clinical research. 
Managing referrals for PET/CT
In both Winnipeg and Halifax, referrals for PET are limited 
to oncology specialists and other select specialists (e.g., lung 
specialists). All PET/CT requests are reviewed by Nuclear 
Medicine PET physicians guided by approved indications 
and CPGs. Local NL specialists consulted for this project 
concur with this approach and support the establishment of a 
committee to develop guidelines and to monitor these activities.
Operating the cyclotron
Having a local cyclotron provides a number 
of important advantages, including potential 
cost-savings, better scheduling of patients, and 
innovative research applications.  Detailed 
explanations can be found in the full report. These 
advantages are so substantial as to suggest that, 
now that the province has decided to purchase 
a cyclotron to support the PET/CT program, 
it should pay serious attention to the optimal 
sequencing of activities so that the cyclotron 
program is initiated as early as possible. 
Experience in Winnipeg and Halifax suggests that, if human 
and financial resources are available for both programs from 
the start, it takes about one year to start up a scanning 
program but two-to-three years to get a cyclotron program 
commissioned. Therefore, unless NL starts development 
of the cyclotron program well in advance, there will be an 
initial period during which PERs will have to be brought in 
from outside the province. The cyclotron suite including the 
research lab requires1500 to 2500 sq. ft. of space.
Human resource requirements
The human resource requirements for both the PET/CT and 
cyclotron programs are considerable and will involve the 
recruitment, remuneration and training of professional and 
technical staff of many types at various stages in program 
development.  
Minimal operational staffing includes specially trained 
physicians, NM technologists, and quality assurance 
technologists, and a regulatory consultant, physicist, 
radiochemist/radiopharmacist, radiation safety officer, cyclotron 
operator, and clinical trials/research coordinator.  
The full CHRSP report provides a summary of the human 
resource requirements for both the PET/CT and cyclotron 
programs along with supporting details for each staff position. 
While NL currently has NM physicians and technologists, 
specialized training will be required in some cases in order 
to establish and maintain competency in PET/CT. Planning for 
training in PET and CT is an important consideration, as is the 
scarcity of radiopharmaceutical and cyclotron scientists, both 
nationally and internationally. 
Regulatory and other requirements 
Significant time and resources must be dedicated to regulatory 
issues involving both Health Canada and the Canadian 
Nuclear Safety Commission. It would be prudent to engage 
a project consultant with specialized expertise in regulatory 
requirements, early in the planning process, as issues related 
to non-compliance can be a significant rate-determining step 
in the process. It has proved impossible to provide a detailed 
program development template because too many factors 
are unpredictable. These include regulatory requirements, the 
procurement process, location (new building or renovated 
space?), the source of FDG while the cyclotron is being 
built, and the availability of construction services and skilled 
operations staff.  The full report, however, presents a generic 
guide to the timelines and sequencing of events for the 
development of a PET/CT program in NL.
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Note: 
1 The half-life is the time it takes an isotope to lose half of its radioactivity.
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are analyzed in terms of their 
applicability to the conditions 
and capacities of the unique 
context of Newfoundland 
and Labrador. CHRSP uses a 
combination of external experts 
and local networks to synthesize 
and contextualize the research 
and to facilitate the uptake of 
the results by local research 
users.
The CHRSP Process
CHRSP endeavors to be timely 
and relevant to research users 
while ensuring a reliable and 
comprehensive process. Our 
goal is to produce a synthesis 
report within six months of 
topic identification.
When the synthesis is complete, 
an external expert reviews 
the work of the project team, 
providing feedback to ensure 
validity. The results of the 
synthesis project are then 
communicated to the province’s 
decision makers and health 
professionals in formats and 
forums designed to maximize 
their uptake into the decision-
making process.
The following policy-relevant suggestions can be drawn from our examination of the best 
available scientific evidence on PET/CT programming as it applies to the context of NL:
Given that the NL Government has declared its intention to purchase PET/CT 1. 
technology and since a PET/CT imaging facility needs to be located in an acute 
tertiary care setting, planning for a PET/CT program should begin immediately 
and should be integrated into the redevelopment of Eastern Health.
The cyclotron facility should be located as close as possible to the PET/CT 2. 
imaging facility. 
The planning process for the cyclotron should begin as soon as possible, and 3. 
certainly no later than the process for the scanner. Both processes should utilize 
expertise that has developed across the country and recruitment should be 
started early in the planning process.
The province will need to develop a list of approved indications for FDG PET/4. 
CT scanning. This list should be evidence-based and guided by accepted Clinical 
Practice Guidelines and it should be revisited periodically and adapted to new 
clinical evidence and to the development of new PERs.
A committee of specialist physicians should be formed to develop clear guidelines 5. 
regarding who would be permitted to order PET/CT scans. All requisitions from 
referring physicians should be screened by NM physicians.
A communications strategy should be developed to inform referring physicians 6. 
and the medical community at large about the approved indications for a PET/
CT and who can order such studies, and to provide guidance on how to interpret 
results. 
The Chief of Nuclear Medicine, the Clinical Chief of Diagnostic Imaging and  7. 
the Vice-President of Medicine should be consulted to establish training and 
experiential guidelines on physician qualifications and continued competency to 
interpret PET/CT studies as well as for a Director of the PET/CT facility. 
Continuing education programs for physicians, nuclear medicine technologists and 8. 
other supporting technical and scientific staff should be developed. 
Human resource needs involving physics, biomedical engineering, and 9. 
radiopharmaceutical support, fulfillment of regulatory requirements, clinical trials 
coordination, and NM technology support should be assessed and adjusted to the 
scope and timelines of the PET/CT and cyclotron programs. 
The sponsorship program in technologist training in NM, including PET/CT, should 10. 
be continued so as to enhance recruitment and retention of technologists in NL.
A communications program will be needed to educate the public about PET/CT 11. 
imaging, the conditions that benefit from its use, and its limitations.
Given the complexities of implementing a PET/CT program and an associated 12. 
cyclotron program, the province of NL and Eastern Health should consider 
consulting other Canadian jurisdictions that have recently completed similar 
processes during the NL planning process.
A strategy to determine the research activities that will be undertaken by the 13. 
facility should be considered including determining the resources required and the 
associated regulatory issues.
For the complete CHRSP report 
on this project, including details 
on the evidence reviewed by the 
project team, see the NLCAHR 
website:
www.nlcahr.mun.ca/research/chrsp
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